<DOC>
	<DOCNO>NCT01900249</DOCNO>
	<brief_summary>The purpose study determine whether 0.2 % 0.5 % R348 Ophthalmic Solutions safe effective treatment Patients Keratoconjunctivitis Sicca .</brief_summary>
	<brief_title>To Assess Safety Efficacy R932348 Ophthalmic Solutions Patients With Keratoconjunctivitis Sicca</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>A history dry eye ( base date initial dry eye symptom ) Use overthecounter ( OTC ) and/or prescription eye drop dry eye symptom Corneal fluorescein stain score least 2 inferior region History , concurrent clinically significant illness , medical condition ( Keratoconjunctivitis Sicca Sj√∂gren 's syndrome ) , laboratory abnormality , Investigator 's opinion , could affect conduct study . Use ophthalmic cyclosporine within 45 day Visit 1 . Use topical ophthalmic steroid within 2 week Visit 1 . Have wear contact lenses anticipate use contact lens study . Have condition situation Investigator feel may put subject significant risk , may confound study result , may interfere significantly subject 's participation study . Have history alcohol substance abuse , judgment Investigator , may impair risk subject 's full participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>